Showing 1–7 of 7 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Padmapriyadarsini Chandrasekharan
…or shorter, tolerable and effective regimen Hence modified BPaL regimen is designed to study the newer shorter oral in varying doses of Linezolid for pre XDR Tb patients and MDR TI/NR patients The regimen proposed is based on the NIX-TB and ZeNIX trial regimen with modification…
Evans D, Hirasen K, Ramushu C, Long L, Sinanovic E, et al.
…ltidrug-resistant (MDR)-TB, pre-extensively drug-resistant (pre-XDR)-TB and XDR-TB. Historically, all variations of DR-TB required treatment with second-line drugs which are less effective and more toxic than first-line options, have a longer treatment duration and are more expen…
Fumagalli G, Riccardi N, Catalano G, Ferrarese M, Repossi AC, et al.
…se of transborder pulmonary pre-extensively drug-resistant (pre-XDR)-TB treated in Italy with the bedaquiline-pretomanid-linezolid regimen. Diagnosis and treatment were started in Ukraine, and, after a month of treatment, due to the Russo-Ukrainian war, the patient moved to Italy…
Oki Nugraha Putra, Ana Khusnul Faizah, Nani Wijayanti Dyah Nurrahman
…ies and a longer duration than drug-sensitive tuberculosis. Pre-XDR and XDR-TB are highly DR-TB with a lower success treatment than MDR-TB. Therapy for high DR-TB with fewer drugs and shorter treatment is required to increase the success of treatment. We comprehensively reviewed …
Neela D. Goswami, Lakshmi Praveena Peddareddy, John Jereb, Angel Colon Semidey, Elaine Darnall, et al.
… U.S. FDA approved pretomanid as part of a 6-month all-oral BPaL (bedaquiline, pretomanid, and linezolid) regimen for treating pulmonary extensively drug-resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). In the study supporting …
Goswami N, Peddareddy L, Jereb J, Semidey A, Darnall E, et al.
… U.S. FDA approved pretomanid as part of a 6-month all-oral BPaL (bedaquiline, pretomanid, and linezolid) regimen for treating pulmonary extensively drug-resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). In the study supporting …
Piamlarp Sangsayunh, Thanyanuch Sanchat, Charoen Chuchottaworn, Krisana Cheewakul, Sirijit Rattanawai
…mary objective of this study was to evaluate the real-world effectiveness, side effects and challenges associated with the implementing of the groundbreaking BPaL-containing regimen in Thailand. Another aim was to investigate the characteristics and severity of the disease, the p…